Published in Nat Med on May 13, 2007
Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 11.80
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol (2009) 5.57
Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol (2007) 5.27
Th17 cells in human disease. Immunol Rev (2008) 4.27
Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A (2009) 4.10
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol (2008) 3.19
Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest (2009) 2.96
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity (2013) 2.69
The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest (2008) 2.66
A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity (2009) 2.59
IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol (2011) 2.44
Retracted Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med (2010) 2.43
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A (2008) 2.33
A look at autoimmunity and inflammation in the eye. J Clin Invest (2010) 2.30
Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum (2008) 2.25
Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol (2008) 2.22
Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci (2010) 2.08
Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett (2008) 2.04
Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med (2014) 1.91
TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol (2009) 1.66
Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev (2010) 1.61
Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60
Interleukin-27: balancing protective and pathological immunity. Immunity (2012) 1.58
Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J Immunol (2009) 1.57
Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood (2008) 1.56
STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine (2009) 1.55
Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol (2012) 1.49
Vitamin D3: a helpful immuno-modulator. Immunology (2011) 1.46
IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44
Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr Opin Allergy Clin Immunol (2012) 1.43
Th17 cells in immunity and autoimmunity. Clin Dev Immunol (2013) 1.40
Immune response and immunopathology during toxoplasmosis. Semin Immunopathol (2012) 1.38
Both Th1 and Th17 are immunopathogenic but differ in other key biological activities. J Immunol (2008) 1.36
Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells. Immunol Res (2008) 1.34
Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease. Arthritis Res Ther (2012) 1.34
STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms. J Immunol (2010) 1.33
New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol (2008) 1.31
Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res (2009) 1.27
Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford) (2009) 1.25
STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem (2011) 1.22
1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One (2010) 1.22
MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord (2010) 1.22
The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol (2010) 1.21
Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Dev Immunol (2013) 1.20
Unlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell death. J Immunol (2009) 1.19
Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol (2008) 1.19
Cytokines in autoimmune uveitis. J Interferon Cytokine Res (2011) 1.19
Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology (2011) 1.19
Immunity to infection in IL-17-deficient mice and humans. Eur J Immunol (2012) 1.18
Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol (2008) 1.12
Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci (Landmark Ed) (2010) 1.11
Perinatal systemic inflammatory response syndrome and retinopathy of prematurity. Pediatr Res (2010) 1.11
MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun (2011) 1.10
Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms. J Immunol (2011) 1.09
Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11.10 mice. Cytokine (2009) 1.08
Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol (2010) 1.07
Helper T-cell differentiation and plasticity: insights from epigenetics. Immunology (2011) 1.07
Desiccating stress induces CD4+ T-cell-mediated Sjögren's syndrome-like corneal epithelial apoptosis via activation of the extrinsic apoptotic pathway by interferon-γ. Am J Pathol (2011) 1.07
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) and IPEX-related disorders: an evolving web of heritable autoimmune diseases. Curr Opin Pediatr (2013) 1.06
Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum (2010) 1.05
Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation. Invest Ophthalmol Vis Sci (2011) 1.05
Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J Biol Chem (2012) 1.04
Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS One (2012) 1.04
Regulation of TH17 cell differentiation by innate immune signals. Cell Mol Immunol (2012) 1.03
The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells. PLoS One (2011) 1.03
New perspectives on effector mechanisms in uveitis. Semin Immunopathol (2008) 1.02
Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. J Immunol (2012) 1.01
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun (2008) 1.01
Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol (2010) 1.00
IL-17A stimulates the production of inflammatory mediators via Erk1/2, p38 MAPK, PI3K/Akt, and NF-κB pathways in ARPE-19 cells. Mol Vis (2011) 1.00
Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res (2011) 1.00
Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci (2011) 1.00
Negative regulation of Th17 responses. Semin Immunol (2008) 0.99
STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Invest Ophthalmol Vis Sci (2013) 0.99
Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice. J Immunol (2011) 0.99
Propionibacterium acnes Induces an IL-17 Response in Acne Vulgaris that Is Regulated by Vitamin A and Vitamin D. J Invest Dermatol (2013) 0.98
Regulation of FoxP3 regulatory T cells and Th17 cells by retinoids. Clin Dev Immunol (2008) 0.98
A suppressive oligodeoxynucleotide inhibits ocular inflammation. Clin Exp Immunol (2009) 0.98
IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells. J Immunol (2014) 0.98
Mouse models of experimental autoimmune uveitis. Ophthalmic Res (2008) 0.97
Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci (2009) 0.97
Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem (2011) 0.97
Suppressors of cytokine-signaling proteins induce insulin resistance in the retina and promote survival of retinal cells. Diabetes (2008) 0.96
IL-22-induced regulatory CD11b+ APCs suppress experimental autoimmune uveitis. J Immunol (2011) 0.96
LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest Ophthalmol Vis Sci (2008) 0.96
Chronic dry eye disease is principally mediated by effector memory Th17 cells. Mucosal Immunol (2013) 0.95
T cells as a therapeutic target in SLE. Lupus (2015) 0.94
Key role for IL-21 in experimental autoimmune uveitis. Proc Natl Acad Sci U S A (2011) 0.94
IL-27-induced modulation of autoimmunity and its therapeutic potential. Autoimmun Rev (2015) 0.94
Neutralization of IL-17 ameliorates uveitis but damages photoreceptors in a murine model of spondyloarthritis. Arthritis Res Ther (2012) 0.93
Complex interactions of transcription factors in mediating cytokine biology in T cells. Immunol Rev (2014) 0.93
Regulatory mechanisms of helper T cell differentiation: new lessons learned from interleukin 17 family cytokines. Pharmacol Ther (2008) 0.93
The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol (2008) 0.93
Association of a NOD2 gene polymorphism and T-helper 17 cells with presumed ocular toxoplasmosis. J Infect Dis (2012) 0.93
The future of uveitis treatment. Ophthalmology (2013) 0.92
IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun (2013) 0.92
Decidual stromal cells recruit Th17 cells into decidua to promote proliferation and invasion of human trophoblast cells by secreting IL-17. Cell Mol Immunol (2014) 0.91
Autoimmune and autoinflammatory mechanisms in uveitis. Semin Immunopathol (2014) 0.91
Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol (2005) 13.50
Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion. J Immunol (2008) 2.90
Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med (2013) 2.85
Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol (2010) 2.50
NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment. Proc Natl Acad Sci U S A (2004) 2.42
Fundus autofluorescence imaging of the white dot syndromes. Arch Ophthalmol (2010) 2.26
Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ (2009) 2.23
Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol (2008) 2.22
Highly coordinated gene regulation in mouse skeletal muscle regeneration. J Biol Chem (2002) 2.17
Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J Immunol (2008) 2.09
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A (2008) 2.07
Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J Immunol (2002) 2.04
The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J (2004) 2.04
Intraocular lymphoma. Curr Opin Ophthalmol (2002) 1.96
Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol (2008) 1.87
The need for standardization of antiretinal antibody detection and measurement. Am J Ophthalmol (2008) 1.83
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology (2009) 1.78
Cyclosporine for ocular inflammatory diseases. Ophthalmology (2010) 1.75
Sympathetic ophthalmia: what have we learned? Am J Ophthalmol (2009) 1.73
Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol (2010) 1.61
Methotrexate for ocular inflammatory diseases. Ophthalmology (2009) 1.58
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm (2007) 1.53
Vitreous cytokine levels. Ophthalmology (2003) 1.48
The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol (2002) 1.48
Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J Immunol (2010) 1.48
Complement component C5a promotes expression of IL-22 and IL-17 from human T cells and its implication in age-related macular degeneration. J Transl Med (2011) 1.47
Protean manifestations of pediatric neurosarcoidosis. Can J Ophthalmol (2009) 1.45
T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest (2005) 1.45
Azathioprine for ocular inflammatory diseases. Am J Ophthalmol (2009) 1.44
Serpiginous choroiditis. Surv Ophthalmol (2005) 1.41
Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol (2009) 1.41
International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm (2008) 1.38
Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol (2005) 1.36
Both Th1 and Th17 are immunopathogenic but differ in other key biological activities. J Immunol (2008) 1.36
Epidemiology and course of disease in childhood uveitis. Ophthalmology (2009) 1.35
Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J Biol Chem (2003) 1.34
Syphilitic outer retinopathy. Ocul Immunol Inflamm (2013) 1.34
Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol (2002) 1.33
Hypomethylation of the IL17RC promoter associates with age-related macular degeneration. Cell Rep (2012) 1.28
Waldenström's macroglobulinemia-associated retinopathy. Ophthalmology (2004) 1.26
Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol (2008) 1.23
Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J Immunol (2004) 1.23
STAT3 protein promotes T-cell survival and inhibits interleukin-2 production through up-regulation of Class O Forkhead transcription factors. J Biol Chem (2011) 1.22
The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol (2010) 1.21
Unlike Th1, Th17 cells mediate sustained autoimmune inflammation and are highly resistant to restimulation-induced cell death. J Immunol (2009) 1.19
T cell tolerance to a neo-self antigen expressed by thymic epithelial cells: the soluble form is more effective than the membrane-bound form. J Immunol (2003) 1.19
Retinal cells suppress intraocular inflammation (uveitis) through production of interleukin-27 and interleukin-10. Immunology (2011) 1.19
Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum (2003) 1.18
Cell proliferation and STAT6 pathways are negatively regulated in T cells by STAT1 and suppressors of cytokine signaling. J Immunol (2004) 1.18
Roles for CXC chemokine ligands 10 and 11 in recruiting CD4+ T cells to HIV-1-infected monocyte-derived macrophages, dendritic cells, and lymph nodes. J Immunol (2005) 1.16
Cyclophosphamide for ocular inflammatory diseases. Ophthalmology (2009) 1.14
Gene expression profiling in autoimmune noninfectious uveitis disease. J Immunol (2008) 1.12
MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun (2011) 1.10
Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol (2004) 1.10
Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Stem Cells (2007) 1.09
Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms. J Immunol (2011) 1.09
Induction of ocular inflammation by T-helper lymphocytes type 2. Invest Ophthalmol Vis Sci (2002) 1.09
A unique pattern of up- and down-regulation of chemokine receptor CXCR3 on inflammation-inducing Th1 cells. Eur J Immunol (2004) 1.08
Emerging drugs for uveitis. Expert Opin Emerg Drugs (2011) 1.08
Diagnosis and management of primary intraocular lymphoma. Hematol Oncol Clin North Am (2005) 1.08
Expression of glucocorticoid induced TNF receptor family related protein (GITR) on peripheral T cells from normal human donors and patients with non-infectious uveitis. J Autoimmun (2003) 1.07
Advances in the diagnosis and immunotherapy for ocular inflammatory disease. Semin Immunopathol (2008) 1.05
Suppressor of cytokine signaling-1 (SOCS1) inhibits lymphocyte recruitment into the retina and protects SOCS1 transgenic rats and mice from ocular inflammation. Invest Ophthalmol Vis Sci (2011) 1.05
Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells. J Biol Chem (2012) 1.04
Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis. PLoS One (2012) 1.04
Risk of hypotony in noninfectious uveitis. Ophthalmology (2012) 1.03
A standardized grading system for scleritis. Ophthalmology (2010) 1.03
Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol (2013) 1.02
Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea (2006) 1.02
High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol (2009) 1.02
High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun (2008) 1.01
Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury. Brain Res (2013) 1.01
Murine model of primary intraocular lymphoma. Invest Ophthalmol Vis Sci (2005) 1.01
Infliximab for the treatment of active scleritis. Can J Ophthalmol (2009) 1.00
The unique features of Th9 cells and their products. Crit Rev Immunol (2012) 1.00
Hypopyon in patients with uveitis. Ophthalmology (2009) 0.99
STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Invest Ophthalmol Vis Sci (2013) 0.99